Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.

Saved in:
Bibliographic Details
Title: Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study.
Authors: Savarirayan R; Murdoch Children's Research Institute, Royal Children's Hospital Victoria, University of Melbourne, Parkville, VIC, Australia. Electronic address: ravi.savarirayan@mcri.edu.au., Irving M; Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK., Wilcox WR; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA., Bacino CA; Baylor College of Medicine, Houston, TX, USA., Hoover-Fong JE; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Harmatz P; UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA., Polgreen LE; Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA., Palm K; Otto-von-Guericke Universität, Universitätskinderklinik, Magdeburg, Germany., Prada CE; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA., Kubota T; Osaka University, Osaka, Japan., Arundel P; Sheffield Children's NHS Foundation Trust, Sheffield Children's Hospital, Sheffield, UK., Kotani Y; Tokushima University Hospital, Tokushima, Japan., Leiva-Gea A; Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Málaga, Spain., Bober MB; Nemours-Alfred I. du Pont Hospital for Children, Wilmington, DE, USA., Hecht JT; McGovern Medical School and School of Dentistry, University of Texas Health, Houston, TX, USA., Legare JM; University of Wisconsin School of Medicine and Public Health, Madison, WI, USA., Lawrinson S; BioMarin (UK) Limited, Ltd., London, UK., Low A; BioMarin (UK) Limited, Ltd., London, UK., Sabir I; BioMarin (UK) Limited, Ltd., London, UK., Huntsman-Labed A; BioMarin (UK) Limited, Ltd., London, UK., Day JRS; BioMarin (UK) Limited, Ltd., London, UK.
Source: Med (New York, N.Y.) [Med] 2025 May 09; Vol. 6 (5), pp. 100566. Date of Electronic Publication: 2024 Dec 30.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101769215 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6340 (Electronic) Linking ISSN: 26666340 NLM ISO Abbreviation: Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-6340
DOI:10.1016/j.medj.2024.11.019